Northwest Biotherapeutics raises $32M in a registered direct offering Northwest Biotherapeutics has entered into an agreement with a single institutional investor for a registered direct placement of up to $32M. The stock purchase agreement provides for the sale of an initial $15M of common stock at $6.60 per share. H.C. Wainwright & Co., LLC acted as the sole placement agent for the transaction.
News For NWBO From The Last 14 Days
Check below for free stories on NWBO the last two weeks.